Lakefront Biotherapeutics American Depositary Shares (LKFT) Stock Price
LKFTStock
$29.90−2.17%52W
Market Cap$1.96B
P/E5.52x
PEG Ratio—
Div yield—
Beta0.18
LKFT Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-21.35%
Price vs S&P 500 (4W)3.98%
VGM Score73.31
P/E Ratio (Annual)5.52x
LKFT Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$12.91 | $0.03 | +100.26%(+$12.94) | |
| Q1 2026 | -$1.09 | $0.24 | +121.65%(+$1.32) | |
| Q4 2025 | -$0.08 | $13.78 | +17634.57%(+$13.85) | |
| Q3 2025 | -$0.32 | -$0.20 | +36.99%(+$0.11) | |
| Q2 2025 | -$0.15 | -$1.05 | -599.47%(-$0.90) |
LKFT Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
2.61
2.61
2.61
2.61
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
LKFTLakefront Biotherapeutics American Depositary Shares | A | B | B | 1.9x | 78.0% | 98.4% | — | $29.90 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Lakefront Biotherapeutics American Depositary Shares
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.